180 related articles for article (PubMed ID: 36276151)
1. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma.
Chen K; Luo CP; Ge DX; Wang KL; Luo Q; Li YZ; You XM; Xiang BD; Li LQ; Ma L; Zhong JH
Front Oncol; 2022; 12():946693. PubMed ID: 36276151
[TBL] [Abstract][Full Text] [Related]
2. Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization.
He C; Ge N; Wang X; Li H; Chen S; Yang Y
Front Oncol; 2022; 12():923566. PubMed ID: 35814420
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
4. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
[TBL] [Abstract][Full Text] [Related]
5. Complete response by patients with advanced hepatocellular carcinoma after combination immune/targeted therapy and transarterial chemoembolization: two case reports and literature review.
Nong X; Zhang YM; Liang JC; Xie JL; Zhang ZM
Transl Cancer Res; 2022 Aug; 11(8):2973-2984. PubMed ID: 36093545
[TBL] [Abstract][Full Text] [Related]
6. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
7. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.
Manjunatha N; Ganduri V; Rajasekaran K; Duraiyarasan S; Adefuye M
Cureus; 2022 Aug; 14(8):e28439. PubMed ID: 36176866
[TBL] [Abstract][Full Text] [Related]
9. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
Front Oncol; 2022; 12():980214. PubMed ID: 36249023
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Li W; Pei Y; Wang Z; Liu J
Front Oncol; 2022; 12():930868. PubMed ID: 35978834
[TBL] [Abstract][Full Text] [Related]
13. Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy.
Wei YG; Su H; Lv ZL; Liao XW; Zeng ZM; Jia YX; Huang HS; Shen XQ; Zhu GZ; Han CY; Ye XP; Peng T
Front Oncol; 2023; 13():1165538. PubMed ID: 37469401
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q
Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350
[TBL] [Abstract][Full Text] [Related]
15. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
[TBL] [Abstract][Full Text] [Related]
16. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
[TBL] [Abstract][Full Text] [Related]
17. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
Xu B; Zhu XD; Shen YH; Zhu JJ; Liu J; Li ML; Tang PW; Zhou J; Fan J; Sun HC; Huang C
Front Immunol; 2022; 13():1016736. PubMed ID: 36505445
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients.
Allgaier HP; Deibert P; Olschewski M; Spamer C; Blum U; Gerok W; Blum HE
Int J Cancer; 1998 Dec; 79(6):601-5. PubMed ID: 9842968
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Tertiary Care Center Experience.
Patidar Y; ; Mukund A; Sarin SK
Indian J Radiol Imaging; 2021 Apr; 31(2):270-276. PubMed ID: 34556907
[No Abstract] [Full Text] [Related]
20. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma.
Cheng JC; Chuang VP; Cheng SH; Huang AT; Lin YM; Cheng TI; Yang PS; You DL; Jian JJ; Tsai SY; Sung JL; Horng CF
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):435-42. PubMed ID: 10802371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
